Compare LAKE & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAKE | ALDX |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.1M | 95.7M |
| IPO Year | 2013 | 2014 |
| Metric | LAKE | ALDX |
|---|---|---|
| Price | $9.32 | $1.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $15.00 | $5.50 |
| AVG Volume (30 Days) | 85.5K | ★ 5.9M |
| Earning Date | 04-16-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $167,211,000.00 | N/A |
| Revenue This Year | $19.75 | N/A |
| Revenue Next Year | $6.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2554.14 | N/A |
| 52 Week Low | $7.15 | $1.07 |
| 52 Week High | $20.50 | $6.18 |
| Indicator | LAKE | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 36.15 |
| Support Level | $8.70 | $1.48 |
| Resistance Level | $9.67 | $2.33 |
| Average True Range (ATR) | 0.43 | 0.12 |
| MACD | 0.17 | 0.13 |
| Stochastic Oscillator | 89.95 | 87.83 |
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe (United Kingdom), and Other Foreign.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.